title: Authors' reply to Braithwaite and Elrington.
authors.affiliation: School of Clinical and Experimental Medicine, College of Medicine and Dental Sciences, University of Birmingham, Birmingham B15 2TT, UK shammuzerengi@yahoo.com.
authors.forename: Sharon
authors.initials: S
authors.lastname: Muzerengi
authors.affiliation: School of Clinical and Experimental Medicine, College of Medicine and Dental Sciences, University of Birmingham, Birmingham B15 2TT, UK.
authors.forename: Carl E
authors.initials: CE
authors.lastname: Clarke
mesh_terms: D000978:Antiparkinson Agents / Q000008:administration & dosage*; D018491:Dopamine Agonists / Q000008:administration & dosage*; D006801:Humans; D007980:Levodopa / Q000008:administration & dosage*; D008996:Monoamine Oxidase Inhibitors / Q000008:administration & dosage*; D018696:Neuroprotective Agents / Q000008:administration & dosage*; D010300:Parkinson Disease / Q000188:drug therapy*
chemical_list: D000978:Antiparkinson Agents; D018491:Dopamine Agonists; D008996:Monoamine Oxidase Inhibitors; D018696:Neuroprotective Agents; D007980:Levodopa